{
    "clinical_study": {
        "@rank": "6756", 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerability of the Chiron vaccine human immunodeficiency virus\n      (HIV) p24(25 or 50 micrograms)/MF59 in healthy HIV-1 seronegative adults. To evaluate the\n      immunogenicity of the HIV p24(50 micrograms)/MF59 vaccine."
        }, 
        "brief_title": "A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults", 
        "condition": [
            "HIV Infections", 
            "HIV Seronegativity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study evaluates the safety and immunogenicity of the Chiron vaccine HIV p24/MF59. In\n      Part A, 15 volunteers are randomly assigned to receive either HIV p24/MF59 or a placebo at\n      0, 1, and 6 months. 10 volunteers receive the vaccine and 5 volunteers receive the placebo.\n      If no serious adverse events are observed within 1 week after the first injection in these\n      first 15 patients, Part B is initiated. In Part B, 25 volunteers are randomly assigned to\n      receive HIV p24/MF59 or a placebo at 0, 1, and 6 months. 20 volunteers receive the vaccine\n      and 5 volunteers receive the placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Volunteers must have:\n\n          -  Good health as determined by medical history, physical examination, and clinical\n             judgment.\n\n          -  Negative serology for HIV infection as determined by licensed HIV ELISA test\n             performed within 6 weeks prior to first immunization.\n\n          -  In vitro Epstein-Barr virus-immortalized cell line from peripheral blood can be\n             established (required for selected Part B volunteers only).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Volunteers with the following symptoms or conditions are excluded:\n\n          -  Significant acute systemic infection.\n\n          -  Occupational or other responsibilities that would prevent completion of participation\n             in the study.\n\n          -  Any condition that might interfere with the evaluation of the study objectives.\n\n        Volunteers with the following prior conditions are excluded:\n\n          -  History of immunodeficiency, autoimmune disease, or any serious chronic illness.\n\n          -  Evidence of psychiatric or medical history or substance abuse that would adversely\n             affect the volunteer's ability to participate in the trial.\n\n          -  History of anaphylaxis or other serious adverse reactions to vaccines or vaccine\n             components.\n\n             1. Immunosuppressive medications.\n\n          -  Live, attenuated vaccine within 60 days of study entry.\n\n        NOTE:\n\n          -  Medically indicated subunit or killed vaccines (e.g., influenza or pneumococcal) are\n             not exclusionary but should be given at least 4 weeks before or after HIV\n             immunizations to avoid potential confusion of adverse reactions.\n\n          -  Experimental agents within 30 days of study entry.\n\n          -  HIV vaccine or MF59 adjuvant. Blood products or immunoglobulins in the past 3 months.\n\n        Engaging in high-risk behavior within 6 months of study entry, i.e.:\n\n          -  injection drug use, sexual intercourse without a condom with 4 or more partners or\n             with known iv drug user or HIV+ partner, or newly acquired sexually-transmitted\n             disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002204", 
            "org_study_id": "095", 
            "secondary_id": "V24P1"
        }, 
        "intervention": {
            "intervention_name": "HIV p24/MF59 Vaccine", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Reference Values", 
            "Placebos", 
            "AIDS Vaccines", 
            "HIV Core Protein p24", 
            "HIV Seronegativity", 
            "MF59 oil emulsion"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Omaha", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68178"
                }, 
                "name": "Creighton Univ Med Ctr / Ped Infect Disease Div"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002204"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiron Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 1999"
    }, 
    "geocoordinates": {
        "Creighton Univ Med Ctr / Ped Infect Disease Div": "41.252 -95.998"
    }
}